APAC Prediabetes Management Market Industry Trends and Forecast to 2034: Segmented by (Approach, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$997.2 MnPlaceholder estimate
Estimate 2025$1.10 Bn22.1% of the global market
Projected 2034$2.68 Bn 143.6%Adds $1.58 Bn over 9 forecast years
CAGR 2025–203410.4%Faster than 50% of 107 Healthcare Services markets here
Key players5
APAC is 22.06% of the global market.
Among regions, the largest is North America at $2.78 Bn.
Omada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA, Teladoc Health (see all)
Active clinical trials
39 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Prediabetes Management Market Analysis Executive Summary
Prediabetes management covers tests, programs, medicines and digital tools that help people with raised blood sugar avoid type 2 diabetes.
Key segments of the prediabetes Management market include approach (Lifestyle Programs, Medication and Digital Coaching) and setting (Primary Care, Workplace Programs and Home).
Asia Pacific Prediabetes Management market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Prediabetes Management Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the prediabetes Management market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the prediabetes Management market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Prediabetes Management Market in APAC
The prediabetes Management market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Prediabetes Management Market in APAC
Prediabetes Management in APAC: payment and research
How care is paid for in some of these countries: Medicare and the PBS (Australia)[1], basic medical insurance (China)[2], the Hospital Authority (Hong Kong)[3], Ayushman Bharat PM-JAY (India)[4], public health insurance (Japan)[5], subsidised public care (Malaysia)[6], Pharmac (New Zealand)[7], PhilHealth (Philippines)[8], MediShield Life (Singapore)[9], the Universal Coverage Scheme (Thailand)[10], JKN (BPJS Kesehatan) (Indonesia)[11], out of pocket and Sehat Sahulat (Pakistan)[12], National Health Insurance (South Korea)[13] and social health insurance (Vietnam)[14]. ClinicalTrials.gov lists 39 studies on Prediabetes Management that are recruiting, active or about to start in APAC.[15]
[15]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Licensing, quality standards and payment models from public and private payers shape how prediabetes Management services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Approach
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Omada Health
7.2 Abbott Laboratories
7.3 Roche Diagnostics
7.4 Merck KGaA
7.5 Teladoc Health
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The prediabetes Management market can be segmented based on various criteria, including approach, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Prediabetes Management right now, from free public sources.
Clinical trials
39 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Prediabetes Management market in Asia Pacific?
Placeholder estimate: about $1.10 Bn in 2025, rising to about $2.68 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Prediabetes Management market in Asia Pacific growing?
Placeholder estimate: about 10.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Prediabetes Management market report cover?
The report splits the market by approach (Lifestyle Programs, Medication, Digital Coaching, Screening and Testing), setting (Primary Care, Workplace Programs, Home) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Prediabetes Management market?
Key players include Omada Health, Abbott Laboratories, Roche Diagnostics, Merck KGaA and Teladoc Health.
What is driving the Prediabetes Management market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the prediabetes Management market.
How many clinical trials on Prediabetes Management are running in Asia Pacific?
39 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Prediabetes Management?
PubMed lists 57 papers on Prediabetes Management added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.